Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.
INTRODUCTION
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages including early restoration of physiological processes, superior conformability, beneficial edge-vascular response and suppression of late-stent malapposition. 1) In addition, 5-years follow-up of BRS showed late lumen enlargement and restoration of vasomotor response and suggested a possible plaque stabilizing effect.
2-4)
However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. They showed that higher rate of procedural related myocardial infarction (MI), and scaffold thrombosis compared with metallic DES. 5)6) Thus, at March 2017, the US Food and Drug Administration (FDA) warned physicians that treating patients with first generation BRS.
BRS has been commercially available in Korea since January 2016, and as of August 2017, about 2,800 BRSs were implanted. However, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. Therefore, at 4th August 2017, 18 Korean heart centers combined efforts to address clinical issues raised by previous studies. We reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management. The scope of this document is limited to the Absorb Bioresorbable Vascular Scaffold (Absorb BRS; Abbott Vascular, Abbott Park, IL, USA), which is the only available BRS in Korea.
DEVICE DESCRIPTION
The Absorb BRS (Abbott Vascular) consists of a 157-μm-thick bioresorbable poly (L-lactide) scaffold with a 7-μm-thick bioresorbable poly (D,L-lactide) coating, which elutes everolimus (7). About 80% of the drug elutes in the first 30 days, and the remainder elutes over 120 days. Scaffold are fully bioresorbable, with complete bioresorption expected by approximately 24 to 36 months. The initial reduction in molecular weight, the decrease in radial support occurs at approximately equal to 6 months, and finally the loss in mass starts at 12 months (Figure 1) . 8) To compared with metallic DESs, BRS has less acute gain, and smaller lumen area. In addition, it has a limited expansion capability. Experimental in-vitro study indicated the fracture threshold was +1.0 mm. Overexpansion beyond this threshold can lead to strut disconnections and focal loss of mechanical support.
9)

CURRENT EVIDENCE Early pilot trials
The ABSORB cohort A and B experiences provided objective characterization of BRS resorption and coronary healing process in humans.
10)11) Serial intravascular imaging studies showed that strut resorption and vascular healing after BRS implantation were associated with late lumen enlargement.
2) The formation of a neointima layer after BRS resorption suggested to seal or "cap" the necrotic core plaque, and to prevent plaque rupture in the future.
3) In addition, the restoration of vasomotor response to stimuli was demonstrated by 5 years.
4) Early promising results called for clinical comparison studies with standard metallic DES.
Randomized trials
ABSORB II is the first randomized controlled trial to compare Absorb BRS with everolimuseluting stent (EES) in 501 patients.
1) The primary endpoint was angiographic vasomotor reactivity after nitrate injection and angiographic late luminal loss. At 1 year, first new or worsening angina was lower with BRS, although clinical outcomes were similar between groups. However, at 3-year follow-up, the vasomotor reactivity, angina status, and exercise capacity were not different. In addition, the late luminal loss was larger in the BRS group. The rate of a device-oriented composite endpoint (DOCE) was significantly higher in the BRS group, mainly driven by target vessel MI. Definite or probable device thrombosis was also significantly higher in the BRS group (Figure 2) .
5)
ABSORB III is the first large-scale, multicenter, randomized trial for US FDA regulatory approval.
7) This study enrolled 2,008 patients with relatively simple coronary lesions. This study demonstrated that the BRS group was non-inferior to the EES group in the respective to target lesion failure (TLF) at 1-year. However, the 2-year results presented at American College of the Cardiology (ACC) 2017 that the rates of TLF were significantly higher in the BRS group due to the increased risk of target vessel MI in the BRS group. However, ABSORB China and ABSORB Japan at EuroPCR 2017 showed that BRS had comparable safety and efficacy to EESs at 3 years.
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Mass loss
Molecular weight Recently, the Amsterdam Investigator-initiateD Absorb Strategy (AIDA) study reported early because of the higher incidence of device thrombosis in the BRS group.
6) This study enrolled 1,845 patients with more complex lesion subset than ABSORB III trial in the context of routine clinical practice: acute coronary syndrome (ACS) was 54% and small vessel disease was about 20%. In addition, postdilatation (74%) was still underused. Although target vessel failure (TVF) was not significantly different, device thrombosis, and subsequently target vessel myocadial infarction were significantly higher in the BRS group. Table 1 summarized currently available randomized trials.
Update meta-analysis of 2-year outcomes from 7 randomized trials showed that BRS had higher 2-year risk of the DOCE than EES. 12) This difference was mainly derived from target vessel MI and ischemic-driven target lesion revascularization (TLR). In addition, device thrombosis was significantly higher in the BRS group. However, cardiac mortality was not different between groups (Figure 3 
Registry studies
The Gauging coronary Healing with bioresorbable Scaffolding plaTforms in EUrope (GHOST-EU) registry evaluated the performance of the Absorb BRS in a real-world practice from 10 European heart centers.
13) The incidence of TLF was 2.2% at 30 days and 4.4% at 6 months. However, definite or probable scaffold thrombosis was 1.5% at 30 days and 2.1% at 6 months. ABSORB expand registry reported that 12-month clinical outcomes in the first 512 patients. 14) At one year, the ischemia-driven TVF was 4.9%. The cumulative rate of definite and probable scaffold thrombosis for this population was 0.8%. A Prospective, Randomized Trial of Bioresorbable Vascular Scaffold Versus Everolimus Eluting Stent in Patients Undergoing Coronary Stenting for Myocardial Infarction (ISAR-ABSORB MI) registry enrolled more complex population with diabetes (31.5%), ACS (39.0%), and bifurcation (13.1%). 15) At 2 years, the composite of death, MI, or TLR occurred in 21.6%. Definite scaffold thrombosis occurred in 3.8%. This study showed the higher event rates than expected, which raised concerns about the daily use of BRS. The Registro Absorb Italiano (RAI) registry enrolled 1,505 patients (22.4% diabetes, 59.6% ACS) from 23 Italian heart centers 16) . All lesions were predilated and 96.8% lesions were post-dilated after BRS implantation. At 30 days, TLR occurred in 0.6% and definite or probable scaffold thrombosis occurred in 0.8%. This registry suggested that when accurate BRS implantation technique was used, an unrestricted BRS use would be safe and effective. [17] [18] [19] [20] [21] In addition, BRS was evaluated in the complex patients and lesions subset including diabetes, 22) ACS, [23] [24] [25] MI, [26] [27] [28] [29] [30] [31] [32] [33] small vessel, 34) and in-stent restenosis. [35] [36] [37] However, the interpretation of such studies should be careful considering the biased nature of registry studies. 
RISK FACTORS FOR SCAFFOLD THROMBOSIS
Risk factors for scaffold thrombosis were multifactorial in the combination of the device, procedural, and patient factors. Mainz IntraCoronAry daTabase (MICAT) registry enrolled 42 scaffold thrombosis. Multivariate analysis showed that ostial lesions and impaired left ventricular ejection fraction were independent predictors of scaffold thrombosis. In addition, early discontinuation of dual antiplatelet therapy (DAPT) was frequent in those patients. Most striking finding was that a BRS-specific implantation strategy reduced 12-months scaffold thrombosis rate from 3.3% to 1.0% (Figure 4) . 18) Recent meta-analysis from ABSORB trials reported that diabetes and preprocedural reference vessel diameter (<2.25 mm vs. ≥2.25 mm) were independent predictors for definite or probable device thrombosis. 12) 800 https://e-kcj.org https://doi.org/10.4070/kcj.2017.0300 
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KOREAN EXPERIENCE
The Absorb BRS has been used since October 2015 in Korea. As of August 2017, a total of 2,833 BRSs were implanted. Among those, only 9 scaffold thrombosis were reported in 9 patients. All patients presented with ACS (5 acute MI, 4 unstable angina). BRSs were implanted under the intracoronary imaging guidance in all cases. Postdilatation was performed in 8 patients. Scaffold thrombosis occurs in 2 cases within 24 hours and in 7 cases between 1 day and 30 days. No late scaffold thrombosis was reported. Possible mechanisms of scaffold thrombosis are early continuation of DAPT in 5 cases, underexpansion in 4 cases, and scaffold malapposition in 1 case. All patients were successfully treated without events (Table 3) Table 4) . Compared with other studies, the IRIS BVS registry had the higher rate of imaging guidance, and pre-and postdilation. This could be a plausible reason of favorable BRS outcomes with very low rate of scaffold thrombosis in Korea, although preliminary.
INDICATIONS FOR BRS IMPLANTATION Patient selection
As current BRSs resolve 2-3 years after implantation, improvement in outcome comparing with metallic DESs is expected in long-term over those periods. Therefore, ideal BRS candidate is a relatively young with a good life expectancy (>5 years). On the other hand, the use of BRS in patients with limited life expectancy with multiple comorbidities, and at high bleeding risk was not supported.
38)
Lesion selection
BRS can be implanted in non-complex lesions including de novo lesions with diameter of 2.25-4.0 mm on on-site quantitative coronary angiography (QCA), relative short lesions, and stable angina presentation. The culprit lesion of ST segment elevated MI, bifurcation lesion treating with 2 scaffolds, and aorto-ostial lesion, extreme tortuous vessel and small vessel (<2.25 mm) were less favorable lesions for BRS implantation. 
BRS specific implantation techniques
Optimal sizing and BRS implantation technique is of paramount importance for achieving favorable long-term outcomes. Operators should understand that thick scaffold struts and their plastic nature results in a lower lumen gain and a smaller post-implanted minimal lumen 802 https://e-kcj.org https://doi.org/10.4070/kcj.2017.0300 diameter compared with conventional metallic DES. Importantly, report that early scaffold thrombosis occurs at a time when most patients received DAPT suggested that scaffold thrombosis would be related to procedure related factors.
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5) In addition, in randomized trials and registry studies, the optimal techniques for BRS implantation was underused. The systemic introduction of a BRS-specific protocol which has come to be known as preparation, sizing, and postdilatation (PSP) are associated with an up to 70% decrease in scaffold thrombosis to rates similar to those reported in metallic DESs (Figure 4) . 18) We suggest the "effective" PSP methods for BRS implantation (Table 6, Figure 5 ).
38)39)
Step
lesion preparation with predilatation
The lesions should be prepared using adequate predilatation with semi or non-compliant balloon (1:1 vessel to balloon ratio). At the same time, operator should be cautious to avoid severe dissection over the BRS covered zone. Particularly for calcified lesions, aggressive lesion preparation is mandatory due to the relatively lack of sufficient radial force in BRS. Scoring/cutting balloon or rotational atherectomy can be used with lower threshold. 40) If predilatation balloons cannot fully expand lesions, BRS implantation should be avoided.
Step 2. sizing and implantation
Intracoronary imaging including intravascular ultrasound or optical coherent tomography is a useful tool to assess pre-intervention lesion characteristics and optimize stent implantation. 41) However, even in clinical trial setting, intracoronary imaging was significantly underused. 7)42)43) In addition, angiography guidance with visual estimation may be inaccurate. 44) 803 https://e-kcj.org https://doi.org/10.4070/kcj.2017.0300 Instead, online QCA with automatic calibration offers reliable assessment of vessel sizing without additional cost. 45)46) We suggest that BRS sizing relies on proximal and distal maximal lumen diameter (Dmax) at the level of intended BRS implantation zone after nitroglycerin administration. 47) Except in case of extreme vessel tapering, the scaffold selection should match the proximal Dmax in proximal device landing zone. Considering Dmax from online QCA is about 0.5 mm smaller than vessel diameter from intracoronary imaging, 48) this sizing method with additional bigger non-compliant balloon inflation can well-negotiate the risk between underexpansion of proximal edge and dissection of distal edge. In addition, this strategy can limit excessive scaffold/artery ratio, and may decrease thrombogenicity, and neointimal thickness.
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49)50)
BRS should cover normal looking segment at either edge of lesion. Scaffold deployment should be performed slowly with long-duration. In general, high-pressure inflation with delivery balloon was not recommended. When implanting multiple BRS, minimal overlapping techniques to minimize scaffold thickness are suggested such as "marker-to marker" (up to 1 mm of overlap) or "scaffold-to-scaffold" (no overlap) technique.
8)
Step 3. postdilatation with a non-compliant balloon Postdilitation is also very important during BRS implantation. In previous registry, all acute or subacute BRS thrombosis occurred in severe underexpanded scaffold. 51) Postdilatation uses a non-compliant balloon with 0.5 mm bigger size than scaffold device with high inflation pressure (16-25 atm) . Recent data showed that higher balloon to artery ratio (>1.2, or balloon to device ratio >1.15) was associated with expansive vessel wall remodeling. 52) Target pressure should be maintained for at least 30 seconds, because a significant larger lumen diameter is obtained with a longer inflation time. 53) On-line QCA showed that proximal Dmax was 3.1 mm and distal Dmax was 2.6 mm (E-G). Predilatation was performed using 3.5×1.5 mm non-compliant balloon (B). Absorb BRS 3.0×23 mm was implanted (C). Postdilatation was done by 3.5×15 mm non-compliant balloon up to 18 atm (final balloon diameter: 3.6 mm). Final optimal coherent tomography showed well expanded and apposed scaffold without acute complications. BRS = bioresorbable vascular scaffold; Dmax = maximal lumen diameter; LAD = left anterior descending; MLD = mean lung dose; NC = non-compliant; PSP = preparation, sizing, and postdilatation; QCA = quantitative coronary angiography; RVD = reference vessel diameter.
TREATMENT FOR BRS FAILURE (SCAFFOLD THROMBOSIS AND IN-SCAFFOLD RESTENOSIS)
Understanding the fundamental pathophysiological mechanism underlying BRS failure is of key importance to guide proper subsequent treatment. 54) Therefore, intracoronary imaging study is highly recommended in cases of BRS failure. 55) Multiple treatment strategy for treating BRS failure was proposed including DES, plane balloon angioplasty, drugcoated balloon, or BRS. 55)56) Mechanical causes can be treated first with balloon angioplasty with non-compliant balloon. In-scaffold restenosis due to neointimal hyperplasia can be treated by a drug-coated balloon. If mechanical factors cannot be corrected by balloon angioplasty, DES implantation can be considered. In addition, if BRS failure occurs 6 months after implantation, DES or BRS implantation can be considered because after 6 months disintegration of the scaffold begin and additional radial strength is necessary.
55)
HYBRID PERCUTANEOUS CORONARY INTERVENTION
Due to the clinical and mechanical limitations of current generation BRS, complex coronary lesions are frequent unsuitable for pure BRS implantation. To minimize the length of permanent metallic caging, and achieving optimal BRS result, hybrid approach in combination of BRS, DES, and drug-coated balloon was proposed. 57) For the BRS less favorable lesion including large vessel, aorto-ostial lesion, side-branch of bifurcation, large size discrepancy, and small vessel, conventional DES was implanted. Drug-coated balloon can be used in small diffuse coronary artery disease. 58) BRS was implanted only in BRS favorable lesions overlapping with DES. Aggressive post-dilatation should be performed at the overlapping site to minimize the risk of late malapposition of metallic DES after complete resorption of BRS.
57)
ANTIPLATELET THERAPY AFTER BRS IMPLANTATION
For metallic DES, at least 6-month DAPT after PCI for stable ischemic heart disease, and 12-month for ACSs are recommended in American and European guidelines. 59)60) However, optimal duration of DAPT for BRS remains to be evaluated. Randomized trials stated the use of DAPT for at least 1 year per protocol. 6)7)42)43) Regarding several reports on early as well as late scaffold thrombosis, 61) some physicians suggest the longer DAPT regimen (>12 months), and/or more potent agents (e.g., ticagrelor or prasugrel) 62)63) or triple antiplatelet therapy, particularly in the early period after BRS implantation. In this context, patients who cannot tolerate a long-term DAPT or are at high risk of bleeding may not be ideal candidate for BRS implantation.
LESSONS FROM FIRST GENERATION ABSORB BRS
At 14th September 2017, Abbott Vascular announced a halt to sales of the Absorb BRS. The experience of the first generation BRS provides the valuable insight for the next generation (Figure 6) . First, the new BRS needs to be mechanically stronger, have thinner struts, and available in a broad range of length and diameter. In addition, complete biodegradation occurs without significant inflammatory reaction within 1-2 years. Second, treating physicians should realize that BRS profiles may differ significantly from conventional metallic DESs and should adopt specific BRS implantation technique for favorable outcomes. Third, new BRS should be extensively tested in a stepwise fashion from relatively simple lesion to more complex lesion.
CONCLUSION
Although promising early reports, recent studies have raised concerns about the safety and efficacy of BRS compared with contemporary standard metallic DESs. However, we have experienced in the interventional technology field that the drawbacks of old device have greatly motivated technological innovation to solve previous problems. With rapid evolving technology of BRS under a number of current ongoing clinical tests, newer BRS overcoming current issues are expected in a near future.
